scholarly journals Assessment of Cholesterol, Glycemia Control and Short- and Long-Term Antihypertensive Effects of Smooth Hound Viscera Peptides in High-Salt and Fructose Diet-Fed Wistar Rats

Marine Drugs ◽  
2019 ◽  
Vol 17 (4) ◽  
pp. 194 ◽  
Author(s):  
Ola Abdelhedi ◽  
Hana Khemakhem ◽  
Rim Nasri ◽  
Mourad Jridi ◽  
Leticia Mora ◽  
...  

In this study, the antihypertensive activity of Purafect®-smooth hound viscera protein hydrolysate (VPH) and its peptide fraction with molecular weight (MW) below 1 kDa (VPH-I) was investigated. In addition, the lipase inhibitory activity, as well the anticoagulant potential, in vitro, were assessed. The antihypertensive effects of VPH and VPH-I were studied during 24 h (short-term effect) and 30 days (long-term effect) using high-salt (18% NaCl) and -fructose (10%) diet (HSFD)-induced hypertension. Data showed that, 4 h post-administration of VPH and VPH-I (200 mg/kg BW), the systolic blood pressure of rats was reduced by about 6 and 9 mmHg, respectively. These effects were similar to that obtained with Captopril (~9 mmHg at t = 4 h). On the other hand, exposing the rats to daily to HSFD, coupled to the administration of viscera peptides, was found to attenuate hypertension. In addition, the proteins’ treatments were able to correct lipid and glycemic disorders, by reducing the total cholesterol and triglyceride contents and resorting to the plasma glucose level, compared to the HSFD group. Overall, the present findings demonstrated the preventive effect of VPH-peptides from hypertension complications, as a result of their biological properties.

2006 ◽  
Vol 17 (6) ◽  
pp. 1045-1049 ◽  
Author(s):  
Gi??dre Berretin-Felix ◽  
Renata Paciello Yamashita ◽  
Hugo Nary Filho ◽  
Eduardo Sanches Gonales ◽  
Alceu Sergio Trindade ◽  
...  

1981 ◽  
Vol 4 (5) ◽  
pp. 218-222 ◽  
Author(s):  
M. Berrettini ◽  
U. Buoncristiani ◽  
P. Parise ◽  
E. Ballatori ◽  
G.G. Nenci

The short- and long-term effect of hemodialysis with two different membranes — cuprophan and polyacrilonytrile — on platelet aggregation has been investigated in 12 uremic patients undergoing extracorporeal dialysis, passing from one treatment to the other. Cuprophan membranes failed to correct the defective platelet aggregation of uremia, and their thrombogenicity was documented by a fall in platelet count and further impairment of platelet aggregation during dialysis. On the contrary, polyacrilonitryle membranes showed the capacity to correct completely but transiently the platelet aggregation, without changes in platelet count. The results indicate that polyacrilonytrile membranes show a better biocompatibility toward platelets than cuprophan membranes.


2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Ana Denise Brandão ◽  
Jeferson Hernandes da Silva ◽  
Sarah Mariane Oliveira Lima ◽  
Leiciane Lima ◽  
Bhianca Loize ◽  
...  

Geoderma ◽  
2010 ◽  
Vol 158 (3-4) ◽  
pp. 173-180 ◽  
Author(s):  
Enke Liu ◽  
Changrong Yan ◽  
Xurong Mei ◽  
Wenqing He ◽  
So Hwat Bing ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document